Sydney, June 8, 2026, 00:02 AEST
CSL Limited moves into the holiday week with Friday’s rally still fresh. Shares finished at A$97.91, up 5.75%, as investors picked up beaten-down health care stocks ahead of the break.
CSL’s rally is in focus now after May’s sharp downgrade, which had investors debating whether CSL’s earnings issues are passing or of its own making. The ASX cash market is shut Monday for King’s Birthday, leaving Friday’s close as the last tradeable price.
CSL moved around a lot last week. Shares opened at A$94.20 on Monday, fell to A$92.24 by Wednesday and touched A$90.00 that day. The stock closed at A$92.59 on Thursday, then jumped Friday, but counting from the previous Friday close of A$96.61, CSL ended up just 1.3% higher for the week.
S&P/ASX 200 slips as banks, miners weigh; CSL lifts health care
The S&P/ASX 200 dropped 0.70% to 8,625.10 on Friday. Banks and miners pushed the index down, with health care the only sector in the green. CSL’s gain offered some support but wasn’t enough to pull the benchmark higher.
CSL wasn’t the only one moving. Stocks Down Under’s Ujjwal Maheshwari said Cochlear was up 5.6%, ResMed gained 4.3%, and Pro Medicus added 4.0%. That suggests buyers were targeting the whole health care group, not just following CSL’s news.
CSL still faces pressure. Reuters, via Sahm Capital, reported that CSL trimmed its fiscal 2026 outlook in May and warned of roughly US$5 billion in non-cash impairments—these are accounting moves that write down assets but don’t affect cash flow right away. The company also projected net profit after tax of about US$3.1 billion on a constant-currency basis, which leaves out foreign exchange swings.
MPC Markets founder and CEO Mark Gardner told Reuters after the May downgrade that “back-to-back downgrades” put a spotlight on CSL’s understanding of its own business. Gardner said the company is in “a complex transformation,” including a search for a permanent CEO and facing revenue pressure in major markets. Sahm
CSL still centers on its core operations: CSL Behring focused on plasma and rare-disease drugs, CSL Seqirus in vaccines, and CSL Vifor in iron deficiency and kidney treatments. But the share price has struggled as each unit is under pressure to deliver more and deliver it faster, following a year of downgrades and write-downs.
CSL interim CEO Gordon Naylor told investors in May the company’s strategy isn’t shifting much and its focus on plasma therapies will continue, according to ABC. Asked if CSL was still a low-cost producer, he said, “Yes, is the short answer,” adding margins were “pretty robust” but “not as good as we’d like.” ABC News
CSL doesn’t have a full-year result out this week. The company’s site puts its full-year end on June 30 and says results with the final dividend will come August 18. That means traders are left to react to market flows, health care stock moves, or any unplanned company updates in the near term.
Friday’s bounce could unwind. If buyers stepped in just ahead of the long weekend and didn’t really change their minds on CSL’s earnings track, the stock might lose some of those gains when markets reopen.
CSL has given itself some breathing room, but nothing more definite. When trading starts after the King’s Birthday holiday, CSL faces a key question: Will buyers step in for the beaten-down health care giant once the market is open again?
